Aptinyx to present NYX-2925 data for chronic pain at IASP

Aptinyx announced the presentation of two posters highlighting preclinical data on novel N-methyl D-aspartate, or NMDA, receptor modulator, NYX-2925, that support its ongoing clinical development for the treatment of chronic pain conditions. Results from the preclinical studies will be presented at the International Association for the Study of Pain’s, or IASP. NYX-2925 has demonstrated activity in preclinical models of numerous neuropathic pain conditions with a favorable tolerability profile. In a Phase 1 clinical study in healthy human subjects, NYX-2925 was well tolerated across a wide dose range, including dose levels well in excess of the expected therapeutic levels. NYX-2925 is currently in Phase 2 clinical development for the treatment of painful diabetic peripheral neuropathy, or DPN, and is also being evaluated in an exploratory Phase 2 study in fibromyalgia. The FDA has granted fast track designation to Aptinyx’s development of NYX-2925 for the treatment of neuropathic pain associated with DPN.
https://thefly.com/landingPageNews.php?id=2790613